Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M |
Gross Profit | -45.00K | 0.00 | -42.32M | -169.00K | -4.00K | 1.43M |
EBITDA | -114.62M | -98.08M | -51.61M | -42.69M | -19.58M | -7.91M |
Net Income | -116.25M | -102.33M | -52.37M | -42.86M | -100.61M | -7.33M |
Balance Sheet | ||||||
Total Assets | 204.48M | 238.99M | 310.13M | 196.59M | 230.33M | 44.43M |
Cash, Cash Equivalents and Short-Term Investments | 149.15M | 171.56M | 243.52M | 177.60M | 194.24M | 43.78M |
Total Debt | 29.00M | 29.70M | 28.49M | 105.00K | 0.00 | 0.00 |
Total Liabilities | 48.96M | 57.18M | 43.15M | 7.81M | 5.15M | 63.02M |
Stockholders Equity | 155.52M | 181.82M | 266.97M | 188.78M | 225.18M | -18.59M |
Cash Flow | ||||||
Free Cash Flow | -102.56M | -86.23M | -43.09M | -35.31M | -18.00M | -7.45M |
Operating Cash Flow | -102.48M | -86.22M | -43.06M | -35.15M | -17.96M | -7.45M |
Investing Cash Flow | 85.92M | 48.03M | -171.67M | 39.19M | -104.12M | 0.00 |
Financing Cash Flow | -215.00K | 6.93M | 151.75M | 3.91M | 200.47M | 44.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $141.75M | ― | -133.65% | ― | 148.33% | 42.41% | |
52 Neutral | $7.45B | 0.30 | -61.93% | 2.28% | 16.62% | 1.04% | |
44 Neutral | $88.18M | ― | -122.69% | ― | ― | 20.91% | |
36 Underperform | $70.27M | ― | -55.68% | ― | ― | -57.45% | |
$61.31M | ― | -20.33% | ― | ― | ― | ||
32 Underperform | $33.91M | ― | -1372.59% | ― | ― | 20.85% | |
$72.79M | ― | -54.30% | ― | ― | ― |
On March 27, 2025, Acumen Pharmaceuticals announced the completion of enrollment for its ALTITUDE-AD Phase 2 study, investigating sabirnetug for early Alzheimer’s disease, with topline results expected in late 2026. The company reported a cash balance of $231.5 million as of December 31, 2024, projected to support operations into the first half of 2027, despite a net loss of $102.3 million for 2024 due to increased R&D expenses.